Skip to main content

Ongoing FDAEvent 99383 (2 months ago)

Arrowhead DE Arrow-LOK Implant

The Arrow-LOK Implant did not undergo required gamma radiation dose audit, which could lead to patient infection.

Moderate risk

Using it may cause temporary or medically reversible health problems. Serious harm is unlikely.

FDA Class II recall · How risk is rated

What to do

What happened

Arrowhead DE LLC of Peachtree City, Georgia, recalled the Arrow-LOK Implant, used for fixation of osteotomies, arthrodeses and reconstruction in the lesser toes following corrective procedures, because the implant did not undergo required gamma radiation dose audit. A potential reduction in sterility assurance could lead to patient infection.

The company began the recall on June 23, 2026, and it was added to the FDA's Enforcement Report on August 14, 2026. Distribution was nationwide in the states of VT, FL, TN, NY, GA, TX, and HI.

Summary by Recall Canary from the FDA notice.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Affected if its UDI-DI and lot code are listed under that product.

  1. Arrow-LOK Implant, REF

    UDI-DI
    • 00855967006035
    • 24662119
    • 00855967006042
    • 24662122
    • 00855967006059
    • 24662125
    • 00855967006066
    • 24662128
    • 00855967006073
    • 00855967006080
    • 24662133
    • 00855967006097
    • 24662135
    • 00855967006110
    • 00855967006127
    • 00855967006134
    • 24662150
    • 00855967006004
    • 24662113
    • 00855967006011
    Lot
    • 21-253519
    • 242162

Details

Company began the recall
Sold in

US Nationwide distribution in the states of Vermont, Florida, Tennessee, New York, Georgia, Texas, Hawaii.

Event ID
99383
Recall No.
Z-2958-2026
Company
Arrowhead DE LLCPeachtree City, Georgia
Recall type
Voluntary: Firm initiated
Customers told by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration